MedTrace Logo

" Treating MS Patients With Lower Extremity Spasticity Using Dysport"

NCT03585569 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-07-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether Dysport® (abobotulinumtoxinA) injections for lower extremity spasticity showed a significant reduction of lower extremity spasticity after being injected with Dysport® (abobotulinumtoxinA) in patients with MS.

Conditions

Interventions

BIOLOGICAL

Abobotulinumtoxin A

Treating Patients with Multiple Sclerosis with lower extremity spasticity using Dysport (Abobotulinumtoxin A)

Sponsors & Collaborators

  • Ipsen

    collaborator INDUSTRY

  • Neurology Center of New England P.C.

    lead OTHER

Principal Investigators

  • Salvatore Q Napoli, MD · Neurology Center of New England P.C.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2019-05-31
Completion
2020-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03585569 on ClinicalTrials.gov